• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

    4.430 -0.350 (-7.32%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 40,382
    Open 4.710
    Bid (Size) 4.200 (100)
    Ask (Size) 4.970 (100)
    Prev. Close 4.780
    Today's Range 4.000 - 4.742
    52wk Range 0.2500 - 7.500
    Shares Outstanding 23,228,941
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill

    Performance

    YTD
    +468.0%
    +468.0%
    1 Month
    +938.2%
    +938.2%
    3 Month
    +515.3%
    +515.3%
    6 Month
    +486.8%
    +486.8%
    1 Year
    +254.4%
    +254.4%

    More News

    Read More
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    Which stocks are moving after the closing bell on Wednesday? ↗
    Via Chartmill
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    The market is filled with gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads
    Via News Direct
    Topics Regulatory Compliance
    News headline image
    Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights ↗
    Via Benzinga
    News headline image
    This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday ↗
    Via Benzinga
    News headline image
    NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
    Via News Direct
    News headline image
    Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
    From Market News Alerts
    Via Business Wire
    News headline image
    Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
    Via News Direct
    Topics Regulatory Compliance
    News headline image
    PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
    From PESG Research
    Via Business Wire
    News headline image
    EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission ↗
    Via Benzinga
    News headline image
    NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
    Via News Direct
    News headline image
    EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug ↗
    Via Benzinga
    News headline image
    NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 ↗
    Via InvestorPlace
    News headline image
    NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 ↗
    Via InvestorPlace
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
    Via InvestorPlace
    News headline image
    NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ↗
    Via Benzinga
    News headline image
    Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is NeuroSense Therapeutics Ltd. - Ordinary Shares publicly traded?
    Yes, NeuroSense Therapeutics Ltd. - Ordinary Shares is publicly traded.
    What exchange does NeuroSense Therapeutics Ltd. - Ordinary Shares trade on?
    NeuroSense Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares?
    The ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares is NRSN on the Nasdaq Stock Market
    What is the current price of NeuroSense Therapeutics Ltd. - Ordinary Shares?
    The current price of NeuroSense Therapeutics Ltd. - Ordinary Shares is 4.430
    When was NeuroSense Therapeutics Ltd. - Ordinary Shares last traded?
    The last trade of NeuroSense Therapeutics Ltd. - Ordinary Shares was at 09/30/26 04:00 PM ET
    What is the market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares?
    The market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares is 102.90M
    How many shares of NeuroSense Therapeutics Ltd. - Ordinary Shares are outstanding?
    NeuroSense Therapeutics Ltd. - Ordinary Shares has 103M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.